Targeting hypoxia in advanced ovarian cancer treatment
Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia
This study is testing a new imaging method to find low-oxygen areas in advanced ovarian cancer to see if it can help doctors understand how these areas affect treatment response.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 79 Years |
| Sex | Female |
| Sponsor | Turku University Hospital Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Turku) |
| Trial ID | NCT04001023 on ClinicalTrials.gov |
What this trial studies
This study aims to identify and locate hypoxic lesions in advanced ovarian cancer using 18F-EF5-PET/CT imaging. By performing targeted surgical sampling, researchers will analyze hypoxic and potentially chemoresistant cancer tissues to uncover molecular differences between hypoxic and non-hypoxic tumors within the same patient. The study also seeks to validate the feasibility of using the EF5 PET-tracer for imaging and to develop a predictive model for chemotherapy response based on imaging data.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-79 with newly diagnosed advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Not a fit: Patients with previous cancer or those who are pregnant or nursing may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatments for patients with advanced ovarian cancer by overcoming chemoresistance.
How similar studies have performed: While this approach is innovative, similar studies using imaging to target tumor hypoxia have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * newly diagnosed advanced epithelial ovarian, primary peritoneal or fallopian tube cancer. * age 18-79 years * informed concent Exclusion Criteria: * previous cancer * pregnancy or nursing
Where this trial is running
Turku
- Turku University hospital — Turku, Finland (Recruiting)
Study contacts
- Study coordinator: Maren Laasik, MD
- Email: maren.laasik@utu.fi
- Phone: +35823130000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.